5:55 - An Icelandic company headquartered in Switzerland
16:29 - Fundraising for long development cycles
19:00 - Doing the only Swiss IPO in 2023
24:23 - Splitting your focus to sell 3 products at once
28:39 - Advantages and disadvantages of being publicly listed
This episode was produced in collaboration with startup days, taking place this year on May 14th 2025. Click here to purchase your ticket.
Click here to check out our free Founders Agreement masterclass, with Melanie Gabriel from Yokoy, Christof Roduner from Scandit, and Viviana Gropengiesser from Talent Kick.
About Riad Sherif:
Riad Sherif is the CEO at Oculis, a company focused on the development of topical treatments for ophthalmic diseases in the back and front of the eye. He holds a MSc in Medical Management from the ESCP Business School and worked at companies like Sanofi, Novartis and Alcon before joining Oculis as CEO in 2017.
Oculis’ pipeline includes a topical eye drop candidate for diabetic macular edema and for the treatment of inflammation and pain following cataract surgery. It also includes a candidate for dry eye disease and for non-infectious anterior uveitis, and a candidate for acute optic neuritis.
The company’s origins are in Iceland, where the OPTIREACH® solubilizing formulation technology was developed by two Icelandic co-founders, Professors Einar Stefánsson and Thorsteinn Loftsson, to enable eye drops to reach the back of the eye. Nowadays Oculis is headquartered in Switzerland, with operations in the US and Iceland. Oculis has raised a total of $284.6M in funding over 13 rounds, and went public in 2023 (the only Swiss IPO of that year) before their product was even live. It is currently at stage 3 of clinical trials.
The cover portrait was edited by www.smartportrait.io
Don’t forget to give us a follow on Twitter, Instagram, Facebook and Linkedin, so you can always stay up to date with our latest initiatives. That way, there’s no excuse for missing out on live shows, weekly giveaways or founders' dinners.